Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at no

7월 8일 08:53

New consortium EUbOPEN will provide tools to unlock disease biology

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and dis

6월 9일 09:24

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis[1]

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional ind

6월 1일 09:02

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin f

5월 27일 10:57

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting t

5월 15일 16:13

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide

Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA

5월 14일 11:39

Boehringer Ingelheim’s Aservo® EquiHaler® wins Red Dot for outstanding design quality

Boehringer Ingelheim is proud to announce that its Aservo® EquiHaler® received a Red Dot Award for product design. Aservo® EquiHaler® is an inhalant therapy licensed for use in horses with severe equi

4월 21일 18:10

European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Boehringer Ingelheim today announced that the European Commission has approved nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.[2] The appro

4월 21일 16:36

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Boehringer Ingelheim has significantly stepped up its support to the fight against Covid-19. A Global Support Program has been set up to bring more financial relief, protective materials and medicine

4월 8일 16:14

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketin

3월 2일 10:08

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) pl

2월 28일 10:25

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow (www.mystudywindow.com), a digital platform empowering patients, families, caregivers, and doctors to

2월 19일 10:26

CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes

Boehringer Ingelheim have announced the results of a subgroup analysis of the CARMELINA® trial which demonstrate that linagliptin did not increase the risk of adverse cardiovascular events or hypoglyc

2월 13일 10:11

Respimat® re-usable inhaler wins 2020 Pharmapack Eco-Design Award

Boehringer Ingelheim announced today that its Respimat® re-usable inhaler device is the winner of the 2020 Pharmapack Eco-Design Award. The Pharmapack Awards celebrate the latest innovations from pack

2월 6일 17:51

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma

Horses with severe equine asthma struggle to breath, even at rest. Last week, the European Commission granted marketing authorization[1] to Boehringer Ingelheim for the new Aservo® EquiHaler® - and ho

2월 5일 08:28

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelhe

1월 10일 08:38

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreas

2019년 11월 18일 10:41

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whet

2019년 11월 13일 10:00

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Boehringer Ingelheim today presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Tar

2019년 10월 30일 10:26

Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)

Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new potential treatment for cystic fibrosis.[1,2] The trial will investigate

2019년 10월 17일 10:45

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes

Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olod

2019년 10월 1일 16:37

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases[1]

Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline

2019년 9월 30일 15:43

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with

2019년 9월 23일 13:10

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial that were presented at the 55th Annual Meeting of the

2019년 9월 20일 09:05

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for

2019년 9월 4일 17:43

페이지당 25개

페이지당 5개페이지당 10개페이지당 25개페이지당 50개페이지당 75개페이지당 100개